Rodent non-genotoxic hepatocarcinogens such as nafenopin suppress spontaneous and transforming growth factor β 1 (TGFβ 1 )-induced rat hepatocyte apoptosis as well as inducing DNA synthesis. We wished to determine if these two processes are associated. In primary rat hepatocytes, nafenopin suppressed apoptosis from 1.9 to 0.63% but more apoptotic bodies were bromodeoxyuridine (BrdU)-labelled (0.35%) than predicted statistically from a random distribution of apoptosis within the cycling and non-cycling populations (0.10%). In contrast, TGFβ 1 induced hepatocyte apoptosis (7.8%) but fewer hepatocytes were BrdUlabelled (0.29%) than predicted (0.82%). Western blot analyses showed that nafenopin and TGFβ 1 had opposing effects on cyclin-dependent kinase 4 (CDK4) protein: nafenopin elevated CDK4 compared with controls, whereas TGFβ 1 caused a reduction. These data suggest that nongenotoxic hepatocarcinogens suppress apoptosis in the non-cycling population of hepatocytes and elevate CDK4 levels, possibly allowing potentially tumourigenic cells to enter the cell cycle.
Introduction
Peroxisome proliferators (PPs), such as the hypolipidaemic drug nafenopin, are non-genotoxic rodent hepatocarcinogens because they do not damage DNA yet chronic exposure of rats and mice results in the development of liver tumours (1) . A more detailed understanding of the mechanisms by which PPs induce hepatocarcinogenesis in rodents would facilitate more robust and more accurate assessment of risk to humans. The liver is a highly quiescent organ in which the majority of cells are in G 0 or a so-called 'deep' G 1 phase. However, hepatocytes can be recruited into the cell cycle by surgical resection of the liver (reviewed in ref. 2) or by a chemical stimulus such as exposure to the PPs (3). In addition, PPs suppress rat hepatocyte apoptosis suggesting that the perturbation of the balance between cell division and cell death may mediate the hepatocarcinogenicity of the PPs (3) (4) (5) (6) . However, the mechanistic basis by which these two effects may combine to alter cell fate is unclear. Specifically, do PPs suppress apoptosis in the majority quiescent population of cells or in the minority cycling population of cells, perhaps allowing damaged cells to proliferate? TGFβ 1 has been shown previously to induce apoptosis in many epithelial cell types including hepatocytes (3, 7, 8) . We have shown previously that PPs can suppress TGFβ 1 -induced apoptosis (2, 5) . TGFβ 1 has been shown to cause a G 1 growth arrest (9) and to inhibit the activation of Rb in primary hepatocytes (10) , possibly by down-regulation of the expression or activation of cyclin dependent kinase 4 (CDK4) (11, 12) . CDK4 is thought to be rate limiting for cell cycle progression since it co-operates with cyclin D in the phosphorylation of the retinoblastoma (Rb) protein during the G 1 phase, thus controlling entry to S phase of the cell cycle (13) . Here we address the hypothesis that PPs may permit entry of normally quiescent hepatocytes into S phase via modulation of CDK4 levels. Also, to understand the co-ordinate action of PPs, we have questioned whether nafenopin suppresses apoptosis preferentially in the quiescent or cycling population of hepatocytes.
Materials and methods

Materials
Nafenopin (2-methyl-2-[p-(1,2,3,4-tetrahydro-1-napthyl)-phenoxyl] propionic acid) was a gift from Ciba-Geigy (Basel, Switzerland). Native human platelet TGFβ 1 was purchased from Sigma (Poole, UK). Fetal calf serum was from Advanced Protein Products (West Midlands, UK). Bromodeoxyuridine (BrdU) and monoclonal anti-BrdU antibody were purchased from Boehringer Mannheim (Lewes, UK). Primary anti-CDK4 monoclonal antibody was from Transduction Laboratories (Lexington, KS). Secondary antibodies were from Dako (Cambridge, UK). Enhanced chemiluminescence detection reagent was from Pierce (Rockford, IL). All other tissue culture reagents were purchased from Bio-Rad (Hemel Hempstead, UK), Flow (Lichfield, UK), Gibco (Paisley, UK) or Sigma.
Preparation of primary hepatocytes
Rat hepatocytes were prepared by collagenase perfusion (14) . Briefly, 180-200 g male (8-10 weeks old) Alderley Park rats (Wistar derived) were subjected to terminal anaesthesia using ether and their livers were perfused with 0.05% w/v collagenase. Digested livers were passed through a 0.125 mm gauze and the resultant cell suspension was washed and counted using a haemocytometer. Viability was determined by trypan blue exclusion. All cell preparations had a viability of 70-95% on isolation.
Culture of primary hepatocytes
Unless otherwise stated, 2ϫ10 6 freshly isolated hepatocytes were placed in 25 cm 2 flasks in 4 ml Williams medium supplemented with 10% fetal bovine serum (heat inactivated), 10 µg/ml insulin, 0.1 mM hydrocortisone, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, termed 'complete medium'. Flasks were precoated with rat tail collagen to aid attachment of hepatocytes. Cultures were maintained at 37°C in a humidified atmosphere and the medium was changed at 4, 24 and every subsequent 48 h after culture establishment.
Treatment of hepatocytes with nafenopin
Nafenopin was added to the medium of hepatocytes from a 400ϫ stock solution in dimethylformamide (DMF). The final concentration of nafenopin used in all experiments was 50 µM. Control flasks were treated with DMF to the same final concentration of 0.25% (v/v). 1 TGFβ 1 (human platelet derived) was added as indicated to the medium of hepatocytes from a 2 µg/ml stock solution in 4 mM HCl, 0.1% bovine serum albumin (BSA). The final concentration of TGFβ 1 used was 5 ng/ml in all experiments. TGFβ 1 was added to the hepatocytes in the continued presence or absence of nafenopin. Control flasks were treated with 4 mM HCl/0.1% BSA to the same final concentration of 0.25% (v/v).
Treatment of cells with TGFβ
Measurement of apoptosis
We have shown previously that apoptotic hepatocytes remain attached to the monolayer and can be detected by Hoechst 33258 staining of condensed chromatin (3, 5) . Apoptotic cells were identified as those with brightly staining, condensed chromatin. Where one apoptotic hepatocyte had generated multiple apoptotic bodies, this was scored as one. A total of 1000 Ϯ 10 cells were counted per flask in 10 random fields.
Co-localization of S phase and apoptosis using BrdU staining Hepatocyte cultures were established as described. After 24 h, all flasks were changed into serum-free conditions with or without nafenopin. BrdU (20 mM final concentration) was added to the cultures. After a further 18 h, TGFβ 1 was added in the continued presence of BrdU and in the presence or absence of nafenopin. Control flasks were treated with the appropriate solvents. After a further 24 h, the monolayers were washed, fixed and made permeable in ice-cold methanol/acetic acid (3:1). Incorporated BrdU was localized using an anti-BrdU antibody followed by a peroxidase-linked secondary antibody and a diamino benzidine (DAB) substrate. Replicative DNA synthesis was measured by scoring the percentage of BrdU-positive nuclei in 10 random fields. A total of 1000 Ϯ 100 cells were counted per flask. The level of apoptosis in the cultures was ascertained via a parallel measurement of apoptosis as described above. In addition, the number of morphologically apoptotic and BrdU-positive nuclei (dual-labelled cells) were scored as a percentage of the total number of BrdU-positive nuclei ( Figure 1A ). A total of 3000 Ϯ 500 BrdU positive nuclei were counted per flask.
Statistical analysis of co-localization of S phase and apoptosis
Statistical analyses were undertaken to determine the probability of the measured frequency of dual-labelled cells in each treatment group being a random occurrence. The expected proportion of dual-labelled cells (assuming a random occurrence) was calculated for each animal within each treatment group as: % S phase ϫ (% apoptosis)/100. The expected value assumes that hepatocytes die to the same extent from cycling and quiescent populations of hepatocytes. The observed proportion of dual-labelled cells was measured as described above. Based on the observed proportion of dual-labelled cells, relative likelihood function graphs and 95% confidence intervals were obtained using maximum likelihood estimation, separately for each animal within each treatment group. All data were evaluated using SAS (15, 16) and the actual occurrence was compared with the expected occurrence.
Evaluation of CDK4 expression in primary hepatocytes by western blotting
Primary hepatocytes were seeded at 2ϫ10 6 cells per 25 cm 2 non-collagencoated flask in complete Williams medium for 24 h. All flasks were then changed into serum-free medium containing either nafenopin (50 µM) or DMF alone. Protein samples were obtained at 8, 12 and 24 h after nafenopin addition. After this 24 h period, TGFβ 1 (5 ng/ml in 4 mM HCl) was added to a further batch of cultures in the continued presence or absence of nafenopin. Protein samples were obtained at 4, 8, 12 and 24 h post-TGFβ 1 addition. The protein samples were prepared by scraping the cells from the flasks into icecold PBS and pooling similar treatments together. The samples were then sonicated and centrifuged in EDTA (1 mM) containing the protease inhibitor phenylmethylsulphonyl fluoride (PMSF). The protein content of the supernatant was calculated using the Bio-Rad protein assay.
SDS-polyacrylamide gels were prepared according to the method of Laemmli and Favre (17) . A 10 µg sample of protein was loaded per lane on to 15% acrylamide gels with 3.5% stacking gels. Proteins were blotted onto nitrocellulose membranes and probed using monoclonal anti-CDK4 antibody. Rabbit anti-mouse secondary antibodies were used to localize the primary antibody. This was detected using enhanced chemiluminescence. The specificity of the anti-CDK4 antibody was verified using a full length CDK4-glutathione S-transferase fusion protein (Santa Cruz Biotechnology, Santa Cruz, CA), which ran at 58 kDa on western blots. Equal protein loading on the western blots was verified by Ponceau S staining.
Results
Co-localization of S phase and apoptosis
Initially, we asked whether spontaneous apoptosis in vitro occurred to a greater extent in cycling or quiescent hepatocytes. Figure 1A shows a typical dual-labelled cell that has incorporated BrdU during S phase and is subsequently showing an apoptotic morphology. The proportion of such dual-labelled cells was measured and compared with the proportion expected if apoptosis had occurred randomly within the population. Figure 1b depicts these data graphically as percentages and shows the mean observed and expected results of three independent experiments (one rat per experiment). Figure 2 shows the statistical analyses of the data carried out to determine the confidence limits of the measured frequency of dual-labelled cells occurring at random. Figure 2 shows results from one of the three animals but is representative of all three.
Under control conditions, there was 11.6 Ϯ 5.5% and 1.9 Ϯ 0.1% S phase and apoptosis, respectively. The level of dual-labelled cells detected was a random occurrence in that the expected (0.23 Ϯ 0.11%) and actual (0.26 Ϯ 0.09%) proportions of dual-labelled cells were approximately equal ( Figures 1B and 3A) . This was supported statistically since the expected proportion of dual-labelled cells lay within the 95% confidence level obtained using the observed result (Figure 2A) . Thus, spontaneous apoptosis occurs to the same extent in quiescent and cycling hepatocytes.
Next we asked if nafenopin suppressed spontaneous apoptosis preferentially in cycling or quiescent hepatocytes. Treatment with 50 µM nafenopin resulted in a suppression of hepatocyte apoptosis from 1.9 Ϯ 0.1 to 0.63 Ϯ 0.06% and an induction of S phase from 11.6 Ϯ 5.5 to 18.4 Ϯ 4.5%. Interestingly, the observed percentage of dual-labelled cells (0.35 Ϯ 0.06%) was three times greater than the expected percentage (0.10 Ϯ 0.03%) ( Figure 1B ). Statistical analysis of this treatment group indicated that the expected proportion of dual-labelled cells was outside the 95% confidence level of the observed distribution ( Figure 2B ) indicating that nafenopin suppressed apoptosis preferentially in the non-cycling population ( Figure 3A) .
Following this, we asked if the growth inhibitory cytokine TGFβ 1 induced apoptosis preferentially in cycling or noncycling hepatocytes. Addition of TGFβ 1 induced hepatocyte apoptosis from 1.9 Ϯ 0.1 to 7.8 Ϯ 0.53% and reduced S phase from 11.6 Ϯ 5.5 to 10.5 Ϯ 2.5%. In contrast to the nafenopin treatment group, there were fewer dual-labelled cells measured (0.29 Ϯ 0.13%) than predicted (0.82 Ϯ 0.23%) by a random distribution ( Figure 1B) . The expected proportion of duallabelled cells was greater than the calculated 95% confidence intervals ( Figure 2C ), suggesting that TGFβ 1 induced apoptosis preferentially in non-cycling hepatocytes ( Figure 3A) .
Next, we asked if nafenopin suppressed TGFβ 1 -induced apoptosis preferentially in cycling or quiescent hepatocytes. The addition of nafenopin to the cultures exposed to TGFβ 1 caused a suppression of the TGFβ 1 -induced apoptosis from 7.8 Ϯ 0.53 to 3.85 Ϯ 0.5%. In this co-treatment group, the distribution of apoptosis among the S-phase labelled and non-labelled cells was returned to a random occurrence ( Figure 1B) . The number of observed dual-labelled cells (0.35 Ϯ 0.05%) corresponded with the expected (0.42 Ϯ 0.12%) proportion of dual-labelled cells, and was well within the 95% confidence limits ( Figure 2D ). This supports the hypothesis that the actions of nafenopin and of TGFβ 1 are both exerted preferentially in the non-cycling population of hepatocytes, thus resulting in an apparently random occurrence of dual-labelled cells ( Figure 3A) .
In summary, this series of experiments show that spontaneous apoptosis occurs at random in cycling and quiescent hepatocytes whereas TGFβ 1 induces apoptosis preferentially in quiescent hepatocytes. Nafenopin suppresses both spontaneous and TGFβ 1 -induced apoptosis preferentially in quiescent cells. 1 Nafenopin not only suppresses apoptosis but also stimulates entry into S phase. We asked whether this was mediated via regulation of the G 1 cyclin-dependent kinase protein, CDK4. Figure 4 shows the expression of CDK4 in primary rat hepatocytes. A single band was detected at 33 kDa in all lanes. CDK4 was detected at low levels in control cultures at 0, 8, 12 and 24 h (Figure 4) and also in the hepatocyte suspension prior to plating (data not shown). Treatment with nafenopin (50 µM) resulted in a marked elevation in the levels of CDK4 compared with the solvent control at all time points. In the presence of the growth inhibitory cytokine and hepatocyte apoptotic stimulus, TGFβ 1 (5 ng/ml), the levels of CDK4 were lower than those observed in control conditions (Figure 4) . The pre-addition of nafenopin to the TGFβ 1 -treated cultures resulted in a significant restoration of the amount of CDK4 detected, compared with that observed in cultures treated with TGFβ 1 alone ( Figures 3B and 4) .
Expression of CDK4 in primary rat hepatocytes in response to nafenopin and TGFβ
Discussion
Non-genotoxic carcinogens (NGCs) cause tumours without damaging DNA, probably by perturbing cell growth regulation (reviewed in ref. 18 ). The PP class of NGCs have been shown to induce hepatocyte S phase and to suppress hepatocyte apoptosis although it remains to be determined how these two processes may act in concert to control cell fate. It has been postulated that the suppression of apoptosis together with the stimulation of S phase may allow clonal expansion of DNAdamaged, potentially tumourigenic cells. We wished to address this hypothesis by determining initially whether apoptosis occurred at random or whether this process was more frequent in cycling or non-cycling cells and subsequently, to determine in which population of cells the effects of nafenopin were exerted.
In control cultures, spontaneous apoptosis was random. However, the level of apoptosis and its distribution was altered by nafenopin, suggesting that nafenopin suppressed apoptosis preferentially in the non-cycling cells, defined as those that had not passed through S phase during the previous 42 h ( Figure 3A) . TGFβ 1 , a negative regulator of growth and potent inducer of apoptosis in the liver (8) , increased the number of apoptotic cells as expected. However, the treatment of hepatocytes with TGFβ 1 resulted in fewer dual-labelled cells than expected suggesting that TGFβ 1 preferentially recruited non-cycling cells into apoptosis ( Figure 3A) . These data could be interpreted in two ways. On the one hand, TGFβ 1 could cause a prolonged cell cycle arrest (long enough to avoid S phase during the 42 h of the assay) followed by apoptosis. TGFβ 1 has been shown to inhibit DNA synthesis in hepatocytes by acting at a point immediately before the G 1 /S border (9) . On the other hand, TGFβ 1 could be recruiting habitually quiescent cells directly into apoptosis. Co-treatment of cultures with TGFβ 1 and nafenopin returned the distribution of apoptosis to a random event, suggesting that nafenopin suppresses both TGFβ 1 -induced and spontaneous apoptosis preferentially in non-cycling cells ( Figure 3A) . The most probable explanation for this latter observation is that the apparently random distribution arises from nafenopin overriding the G 1 block imposed by TGFβ 1 , which allows more cells to enter the cell cycle.
TGFβ 1 is known to cause G 1 cell cycle arrest by preventing the expression or activation of CDK4 (11, 12) , and thus the phosphorylation of the Rb protein (13) . Our data demonstrate that nafenopin causes an elevation in CDK4 expression over control cultures consistent with the ability of this PP to induce hepatocyte S phase in vitro (3) ( Figure 3B ). As reported previously (11), TGFβ 1 repressed CDK4 expression. However, nafenopin was able to override this effect of TGFβ 1 by up-regulating CDK4 levels, which may be responsible for permitting a higher level of S-phase entry compared with TGFβ 1 -treated cultures alone. CDK4 is rate-limiting for cell cycle progression since it co-operates in the phosphorylation of the Rb protein (13) . The mechanism by which TGFβ 1 induces hepatocyte apoptosis remains to be determined but, like S-phase entry, may be linked to Rb status. TGFβ 1 has been shown to inhibit the activation of Rb in primary hepatocytes resulting in apoptosis (10) and overexpression of the active (hyperphosphorylated) form of Rb inhibits TGFβ 1 -induced apoptosis in a hepatoma cell line (10) . The perturbation of cell cycle control as a mechanism of action of PPs is supported by recent observations that administration of the PP Wyeth 14 643 in vivo resulted in the differential expression of cell cycle proteins (19) . The extrapolation of these data to the whole animal model should be made with caution since the response of hepatocytes may be modified by the process of removing them from their in vivo trophic support and by their culture conditions. However, in many key respects this model mimics the in vivo situation very well as demonstrated by the suppression of apoptosis, increase in proliferation and regulation of cell cycle proteins (3, 19, 20) .
In summary, the NGC and PP nafenopin suppresses apoptosis preferentially in those hepatocytes in G 0 or a deep G 1 phase of the cell cycle. In parallel, nafenopin elevates CDK4, which may permit cell cycle entry. Our data imply that nafenopinmediated elevation of CDK4 may be the mechanism whereby PPs increase S-phase entry. The exact mechanism by which nafenopin suppresses apoptosis remains to be determined, but may also involve modulation of CDK4.
